Pure Global AI
NCT06254014Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of JY09 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
Beijing Dongfang Biotech Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Type 2 Diabetes Mellitus
Drug/Device/Intervention
Exendin-4 Fc fusion protein injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Dongfang Biotech Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 3
Start date
Mar 01, 2024
End date
Dec 30, 2025
Enrollment
270 participants
Primary outcome

HbA1c

Summary

The main purpose of this study is to investigate the efficacy and safety of JY09 versus
 placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and
 exercise alone

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06254014
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06254014 through Pure Global AI's free database. This Phase 3 trial is sponsored by Beijing Dongfang Biotech Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 270 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.